Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > JP Morgan Conference
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(76)
•••
Comment by Straylighton Jan 10, 2021 3:10pm
185 Views
Post# 32263721

RE:RE:RE:JP Morgan Conference

RE:RE:RE:JP Morgan Conference I checked some of the other companies Stern represents and they have the same time listed too. Maybe the video presentation gets opened for viewing at that time for all of them?

also interesting write up in that link for Antibe:

Antibe is a late-stage biotechnology company leveraging its unique hydrogen sulfide platform to develop next-generation, safer medicines for the treatment of pain and inflammation. Antibe is developing three assets that seek to overcome the gastrointestinal damage caused by existing NSAIDs, with lead asset otenaproxesul entering Phase III for osteoarthritis pain following robust safety and efficacy data. Pipeline also includes two preclinical assets: a non-opioid for peri-operative pain and a gastrointestinal-safe alternative to low-dose aspirin.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities